ERICH CONRAD: Open Payments
NPI 1861414633 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,772 in 96 payments from 13 companies in 2025. Trend: 2023 $1,535 · 2024 $1,077 · 2025 $1,772
Food & beverage: $1,734Education: $39
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $398 |
| Janssen Pharmaceuticals, Inc | 18 | $311 |
| Teva Pharmaceuticals USA, Inc. | 14 | $231 |
| Alkermes, Inc. | 10 | $169 |
| ABBVIE INC. | 12 | $161 |
| Supernus Pharmaceuticals, Inc. | 2 | $112 |
| Vanda Pharmaceuticals Inc. | 5 | $91 |
| Lundbeck LLC | 4 | $90 |
| Neurocrine BioSciences, Inc. | 3 | $85 |
| Axsome Therapeutics, Inc. | 2 | $45 |
Products named: REXULTI, SPRAVATO, ABILIFY ASIMTUFII, UZEDY, VRAYLAR, ARISTADA, Qelbree, FANAPT.
Industry payments across LA — which companies pay providers there.
